文献速递银屑病与炎症性皮肤病

依那西普治疗阿达木单抗继发失效的中重度斑块状银屑病开放标签研究

Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.
PubMed 文献 · Br J Dermatol · 2017-07-19

BACKGROUND: Some patients with plaque psoriasis experience secondary failure of tumour necrosis factor inhibitor therapy. OBJECTIVES: To evaluate efficacy, safety and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure.…

要点

  • 阿达木单抗继发失效患者换用依那西普仍可获得满意应答
  • 抗阿达木单抗抗体状态不影响依那西普的疗效
  • 瘙痒、疼痛、脱屑等患者报告结局在第12周改善并维持至第24周

核心结论

  • 阿达木单抗继发失效的银屑病患者换用依那西普可获得满意应答,且与抗阿达木单抗抗体状态无关。

研究设计与样本

  • 入组为曾用阿达木单抗达到sPGA 0/1后失效(sPGA≥3或失去PASI 50应答)者,基线体表面积≥10%、sPGA≥3、PASI≥10。
  • 依那西普50 mg每周两次共12周,之后50 mg每周一次;主要终点为第12周sPGA 0/1(意向性治疗分析,未检验假设)。

主要发现

  • 未观察到新的安全信号。
  • 瘙痒、疼痛和脱屑的患者报告结局在第12周持续改善,并维持至第24周。

关键数值与推荐

  • 主要终点为第12周sPGA 0/1;继发失效定义为sPGA≥3或失去PASI 50改善。
  • 基线要求体表面积≥10%、sPGA≥3、PASI≥10;依那西普50 mg每周两次12周后改为50 mg每周一次。

临床怎么用

  • 对阿达木单抗继发失效的中重度斑块状银屑病患者,可考虑换用依那西普,且无需依据抗阿达木单抗抗体状态选择。
  • 换药后应关注第12周sPGA与PASI应答,并随访瘙痒、疼痛、脱屑等症状改善情况。

局限性

  • 为开放标签单臂研究,未设对照,主要终点未做假设检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some patients with plaque psoriasis experience secondary failure of tumour necrosis factor inhibitor therapy. OBJECTIVES: To evaluate efficacy, safety and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure. METHODS: This phase IV open-label single-arm estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static Physician's Global Assessment (sPGA) score 0/1 (clear/almost clear). Patients subsequently lost response, defined as sPGA ≥ 3 or loss of 50% improvement in Psoriasis Area and Severity Index (PASI 50). At baseline, patients had involved body surface area ≥ 10%, sPGA ≥ 3 and PASI ≥ 10. Antiadalimumab antibodies (ADAs) were measured at screening. Patients received etanercept 50 mg twice weekly for 12 weeks, followed by 50 mg weekly. The primary end point was sPGA 0/1 at week 12 (intention-to-treat analysis; no hypothesis tested). Additional outcomes included rates of sPGA 0/1, PASI responses, safety, PROs of itch, pain and flaking, Dermatology Life Quality Index, treatment satisfaction and Work Productivity and Activity Impairment questionnaire. RESULTS: Sixty-four patients enrolled; 67% had ADAs. sPGA 0/1 rates at week 12 were 39·7% [95% confidence interval (CI) 27·6-52·8; primary end point] and 45% (95% CI 29·3-61·5) for patients positive for ADAs and 35% (95% CI 15·4-59·2) for patients negative for ADAs. PASI 75 response rates at week 12 were 47·5% (95% CI 31·5-63·9) for patients who were positive for ADAs and 50% (95% CI 27·2-72·8) for patients negative for ADAs. No new safety signals were observed. PROs of itch, pain and flaking consistently improved at week 12 and were maintained through week 24. CONCLUSIONS: Patients with psoriasis who experienced secondary failure of adalimumab achieved satisfactory response to etanercept regardless of ADA status.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Bagel J, Tyring S, Rice KC, et al. Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. Br J Dermatol. 2017. PMID: 28196270. doi:10.1111/bjd.15381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。